文献速递心力衰竭与心肌病

心衰试验能从肿瘤试验中学到什么?

What can heart failure trialists learn from oncology trialists?
PubMed 文献 · Eur Heart J · 2021-01-01

过去二十年(1997-2018)全球心血管疾病和癌症死亡率变化不大,心衰5年死亡率仍高达45-55%。同期癌症药物获批比例远超心血管药物(2018年FDA批准药物中癌症药占27%,心血管药仅占1%,20年间美国仅批准4种心衰药)。

要点

  • 心衰5年死亡率仍高达45-55%,而心血管药物获批数量远落后于肿瘤药物。
  • 肿瘤试验通常规模更小、随访更短、靶向治疗常见,或可借鉴至心衰研究。
  • 需重新评估心血管临床试验的设计、执行和目的,以加速新药研发。

核心结论

  • 心衰试验可借鉴肿瘤试验中小样本、短随访和靶向治疗等元素,以简化流程并降低成本。

主要发现

  • 1997-2018年全球心血管疾病和癌症死亡率变化不大,心衰5年死亡率仍达45-55%。
  • 2018年FDA批准药物中癌症药占27%,心血管药仅占1%;20年间美国仅批准4种心衰药。

临床怎么用

  • 心衰临床试验可参考肿瘤试验模式,采用更小样本、更短随访和靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Globally, there has been little change in mortality rates from cardiovascular (CV) diseases or cancers over the past two decades (1997-2018). This is especially true for heart failure (HF) where 5-year mortality rates remain as high as 45-55%. In the same timeframe, the proportion of drug revenue, and regulatory drug approvals for cancer drugs, far out paces those for CV drugs. In 2018, while cancer drugs made 27% of Food and Drug Administration drug approvals, only 1% of drug approvals was for a CV drug, and over this entire 20 year span, only four drugs were approved for HF in the USA. Cardiovascular trialists need to reassess the design, execution, and purpose of CV clinical trials. In the area of oncology research, trials are much smaller, follow-up is shorter, and targeted therapies are common. Cardiovascular diseases and cancer are the two most common causes of death globally, and although they differ substantially, this review evaluates whether some elements of oncology research may be applicable in the CV arena. As one of the most underserved CV diseases, the review focuses on aspects of cancer research that may be applicable to HF research with the aim of streamlining the clinical trial process and decreasing the time and cost required to bring safe, effective, treatments to patients who need them. The paper is based on discussions among clinical trialists, industry representatives, regulatory authorities, and patients, which took place at the Cardiovascular Clinical Trialists Workshop in Washington, DC, on 8 December 2019 (https://www.globalcvctforum.com/2019 (14 September 2020)).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zannad F, Cotter G, Alonso Garcia A, et al. What can heart failure trialists learn from oncology trialists? Eur Heart J. 2021. PMID: 34076243. doi:10.1093/eurheartj/ehab236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。